Showing 47 RESULTS FOR
Brain disorder research
Parkinson’s Research Update: Multifaceted Approach for a Multifaceted Disease
How insights into Parkinson’s neuropathology are shaping potential transformational approaches.
Lundbeck completes the acquisition of Alder BioPharmaceuticals - a company committed to transforming migraine treatment and prevention
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumab
Futurecast: Exploring the New Era of Psychiatric Research
An update on new directions in psych research and the future of personalized medicine.
Lundbeck to Acquire Alder BioPharmaceuticals – a Company Committed to Transforming Migraine Treatment and Prevention – in a Transaction Valued at up to USD 1.95 Billion Net of Cash
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumab